Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2025-04-08 00:00:00 ET · period of report 2025-04-05 · accession 0001415889-25-010424 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-08 | 2025-04-05 | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | — | +5,275 | 62.2K | +9% | — |
| D | 2025-04-08 | 2025-04-08 | ACAD | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $14.82 | -2,708 | 59.5K | -4% | -$40.1K |
| D | 2025-04-08 | 2025-04-05 | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | $0.00 | -5,275 | 5,276 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-05 | M | A | 5,275 | — | 62,164 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| 2 | Common | Common Stock | 2025-04-08 | S | D | 2,708 | $14.82 | 59,456 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2025-04-05 | M | D | 5,275 | $0.00 | 5,276 | D | — · — to — | 5,275 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F3) The restricted stock units vest in four equal annual installments beginning April 5, 2023. |